Table 3.
Urinary amino acid excretion in healthy controls versus hypertensive patients with nephropathy
| HUNT cohort |
SUGAR cohort |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Central location difference (Nephroscl. – Ctrl., medians) |
Distribution difference (Kolmogorov-Smirnov) |
Discrimination (PLS-DA) |
Central location difference (Nephroscl. – Ctrl., medians) |
||||||
| Δ % | Raw P value | FDR <0.10 | Raw P value | FDR <0.10 | VIP score | Δ % | Raw P value | FDR <0.10 | |
| Carnosine (Car) | −71.1 | 0.15 | N.s. | 0.03 | Sign. | 1.25 | n.a. | n.a. | n.a. |
| Glycine (Gly) | −58.1 | 0.11 | N.s. | 0.06 | N.s. | 1.18 | −35.8 | <0.001 | Sign. |
| Serine (Ser) | −55.4 | 0.06 | N.s. | 0.001 | Sign. | 1.01 | −69.6 | <0.001 | Sign. |
| Tyrosine (Tyr) | −46.9 | 0.03 | N.s. | 0.005 | Sign. | 1.40 | −45.1 | 0.04 | Sign. |
| Threonine (Thr) | −46.7 | 0.19 | N.s. | 0.02 | Sign. | <1.0 | +12.8 | 0.21 | N.s. |
| Histidine (His) | −42.9 | 0.14 | N.s. | 0.24 | N.s. | 1.41 | n.a. | n.a. | n.a. |
| 2.4-diaminobutyric acid | +35.8 | 0.4 | N.s. | 0.7 | N.s. | 1.02 | n.a. | n.a. | n.a. |
| Dopamine (DA) | −35.4 | 0.05 | N.s. | 0.05 | Sign. | 1.0 | −28.2 | 0.05 | Sign. |
| Ornithine (Orn) | −35.2 | 0.04 | N.s. | 0.02 | Sign. | 1.03 | n.a. | n.a. | n.a. |
| Phenylalanine (Phe) | −33.4 | 0.07 | N.s. | 0.009 | Sign. | 1.08 | −51.2 | 0.004 | Sign. |
| Homocysteine (Hcys) | −32.7 | 0.02 | N.s. | 0.009 | Sign. | 1.82 | n.a. | n.a. | n.a. |
| Leucine (Leu) | −32.6 | 0.09 | N.s. | 0.006 | Sign. | <1.0 | n.a. | n.a. | n.a. |
| Kynurenine (Kyn) | −31.9 | 0.06 | N.s. | 0.1 | N.s. | 1.38 | −21.2 | 0.31 | N.s. |
| Lysine (Lys) | −31.8 | 0.11 | N.s. | 0.08 | N.s. | 1.08 | n.a. | n.a. | n.a. |
| Alanine (Ala) | −31.8 | 0.13 | N.s. | 0.1 | N.s. | <1.0 | −63.1 | <0.001 | Sign. |
| α-aminoadipic acid (Aaa) | −31.5 | 0.1 | N.s. | 0.15 | N.s. | 1.07 | |||
| Valine (Val) | −30.3 | 0.18 | N.s. | 0.11 | N.s. | <1.0 | |||
| Cystathionine (Cth) | −29.2 | 0.11 | N.s. | 0.17 | N.s. | 1.15 | |||
| Proline (Pro) | −27.8 | 0.07 | N.s. | 0.03 | Sign. | <1.0 | |||
| Glutamic acid (Glu) | −26.6 | 0.04 | N.s. | 0.05 | Sign. | 1.43 | |||
| Glutamyl-Lysine (Glu-Lys) | −26.1 | 0.17 | N.s. | 0.27 | N.s. | <1.0 | |||
| 5-aminovalerate (5Aval) | −25.5 | 0.48 | N.s. | 0.51 | N.s. | <1.0 | |||
| Methionine (Met) | −24.9 | 0.09 | N.s. | 0.09 | N.s. | 1.20 | |||
| Isoleucine (Ile) | −24.6 | 0.13 | N.s. | 0.15 | N.s. | <1.0 | |||
| 2,6-Aminopimelat (Dapa) | +22.8 | 0.21 | N.s. | 0.2 | N.s. | <1.0 | |||
| Proline-OH-proline (PHP) | −22.1 | 0.68 | N.s. | 0.29 | N.s. | <1.0 | |||
| 1-Met-Histidine (1Mhis) | −22.1 | 0.64 | N.s. | 0.57 | N.s. | <1.0 | |||
| Cystine | −20.9 | 0.05 | N.s. | 0.04 | Sign. | 1.24 | |||
| Hydroxyproline (Hyp) | −15.6 | 0.49 | N.s. | 0.65 | N.s. | <1.0 | |||
| Aspartic acid (Asp) | −9.3 | 0.51 | N.s. | 0.69 | N.s. | <1.0 | |||
| 3-Met-Histidine (3Mhis) | −3.4 | 0.85 | N.s. | 0.45 | N.s. | <1.0 | |||
Note: We intended to replicate the top 15 HUNT metabolites in the SUGAR cohort, but not all metabolites were available and some are therefore marked with “n.a.” Central location is the difference between median values, that is, controls (Ctrl.) subtracted from patients with nephrosclerosis (Nephroscl.).
FDR, false discovery rate; HUNT, Nord-Trøndelag Health Study; N.s, not significant; PLS-DA, partial least squares discriminant analysis; Sign., significant; SUGAR, Study of Glucose and Insulin in Renal Disease; VIP, variable importance in projection.